Contact usContact us

The Company

Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.

Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.

Domain Therapeutics applies a multi-string corporate strategy to grow its business through:

  • validation of its technologies through collaborative partnerships with Pharma/Biotechs,
  • generation of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS and oncology,
  • valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies.

Domain Therapeutics
Last News

FEBRUARY, 8 2017

Prexton Therapeutics closes a series B ($31M) to progress Foliglurax in phase II

Learn more...

JANUARY, 23 2017

Domain Therapeutics and Merck enter into a license and collaboration agreement for development of adenosine receptor antagonists in immuno-oncology

Learn more...  

JANUARY, 19 2017

Domain Therapeutics will attend the AACR Conference on April 1-5 2017  in Washington, USA.

Learn more...

DECEMBER, 14 2016

Domain Therapeutics grants Alkermes a non-exclusive license for its G Protein-Coupled Receptor BioSens-All™ technology

Learn more...